Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cyclacel Pharmaceuticals, Inc. (CYCC : NSDQ)

• Company Description    CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and cutaneous T-cell lymphoma. Seliciclib (CYC202 or R-roscovitine), a CDK inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer. Number of Employees: 12

• Price / Volume Information    Yesterday's Closing Price: $0.65 Daily Weekly Monthly 20 Day Moving Average: 53,000 shares Shares Outstanding: 12.54 (millions) Market Capitalization: $8.20 (millions) Beta: 1.11 52 Week High: $2.41 52 Week Low: $0.50 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 26.83% 22.02% 12 Week -9.13% -15.64% Year To Date -1.90% -10.77%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 200 CONNELL DRIVE SUITE 1500 - BERKELEY HEIGHTS,NJ 07922 USA ph: 908-517-7330 fax: 866-271-3466 ir@cyclacel.com http://www.cyclacel.com

• General Corporate Information    Officers Spiro Rombotis - Chief Executive Officer and President Christopher Henney - Chairman Robert Spiegel - Vice Chairman Paul McBarron - Chief Operating Officer; Chief Financial Officer a Samuel L. Barker - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 23254L603 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/23 Next Expected EPS Date: 08/09/23 Share - Related Items Shares Outstanding: 12.54 Most Recent Split Date: 4.00 (0.05:1) Beta: 1.11 Market Capitalization: $8.20 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.57 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.64 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/09/23

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.81 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -11.90% vs. Previous Quarter: 21.67% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/23 - -117.51 12/31/22 - -83.79 09/30/22 - -62.22 ROA 03/31/23 - -78.99 12/31/22 - -63.52 09/30/22 - -51.48 Current Ratio 03/31/23 - 2.59 12/31/22 - 3.30 09/30/22 - 6.41 Quick Ratio 03/31/23 - 2.59 12/31/22 - 3.30 09/30/22 - 6.41 Operating Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Net Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Pre-Tax Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Book Value 03/31/23 - 0.81 12/31/22 - 1.24 09/30/22 - 1.76 Inventory Turnover 03/31/23 - - 12/31/22 - - 09/30/22 - - Debt-to-Equity 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00 Debt-to-Capital 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00

Powered by Zacks Investment Research ©